DUBLIN, Jan. 20, 2022 /PRNewswire/ — The "Consumer Healthcare Market Research Report by Product, by Distribution, by Region – Global Forecast to 2027 – Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Consumer Healthcare Market size was estimated at USD 318.02 billion in 2020, is expected to reach USD 340.03 billion in 2021, and is projected to grow at a CAGR of 7.28% to reach USD 520.32 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across five major currencies – USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2027 are considered the forecast period.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Consumer Healthcare Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Consumer Healthcare Market, including Abbott Laboratories Inc., American Health Corporation, BASF SE, Bayer AG, Bionova Lifesciences, Boehringer Ingelheim GmbH, Eli Lilly and Company, Endo Pharmaceuticals PLC, Gemini Pharmaceuticals, Geneva Biocare, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Ipsen SA, Jasco Group of Companies, Johnson & Johnson Private Ltd, Koninklijke DSM N.V., Lonza Group Ltd., Novartis AG, Pfizer Inc., Piramal Enterprises Ltd., PureTek Corporation, Reckitt Benckiser (RB) Group PLC, Reckitt Benckiser LLC., ROHN HealthCar, Sanofi S.A., Stanex Drugs & Chemicals Pvt. Ltd, Sterling Pharmaceutical Services LLC, Sun Pharmaceutical Industries Limited, Takeda Pharma, and Teva Pharmaceutical Industries Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Consumer Healthcare Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Consumer Healthcare Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Consumer Healthcare Market?
4. What is the competitive strategic window for opportunities in the Global Consumer Healthcare Market?
5. What are the technology trends and regulatory frameworks in the Global Consumer Healthcare Market?
6. What is the market share of the leading vendors in the Global Consumer Healthcare Market?
7. What modes and strategic moves are considered suitable for entering the Global Consumer Healthcare Market?
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High demand for self-medication
5.1.1.2. Analgesics penetration rising with increasing accessibility
5.1.1.3. Government support to offer affordable and easy access to healthcare
5.1.1.4. Rising geriatric population more prone to contracting diseases
5.1.2. Restraints
5.1.2.1. Inconsistent regulatory framework in different countries
5.1.3. Opportunities
5.1.3.1. Drastic shift from medication prescription to OTC products
5.1.3.2. Accelerated use of online sources
5.1.3.3. Growing demand for branded products and private labels
5.1.4. Challenges
5.1.4.1. Prevention of overuse by the consumers
5.1.4.2. Drastic shift from medication prescription to OTC products
5.2. Cumulative Impact of COVID-19
6. Consumer Healthcare Market, by Product
6.1. Introduction
6.2. Dietary Supplements
6.3. OTC Pharmaceuticals
7. Consumer Healthcare Market, by Distribution
7.1. Introduction
7.2. Departmental Stores
7.3. Independent Retailers
7.4. Pharmacies or Drugstores
7.5. Specialist Retailers
7.6. Supermarkets or Hypermarkets
8. Americas Consumer Healthcare Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Consumer Healthcare Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Consumer Healthcare Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbott Laboratories Inc.
12.2. American Health Corporation
12.3. BASF SE
12.4. Bayer AG
12.5. Bionova Lifesciences
12.6. Boehringer Ingelheim GmbH
12.7. Eli Lilly and Company
12.8. Endo Pharmaceuticals PLC
12.9. Gemini Pharmaceuticals
12.10. Geneva Biocare
12.11. GlaxoSmithKline plc
12.12. Glenmark Pharmaceuticals Ltd.
12.13. Ipsen SA
12.14. Jasco Group of Companies
12.15. Johnson & Johnson Private Ltd
12.16. Koninklijke DSM N.V.
12.17. Lonza Group Ltd.
12.18. Novartis AG
12.19. Pfizer Inc.
12.20. Piramal Enterprises Ltd.
12.21. PureTek Corporation
12.22. Reckitt Benckiser (RB) Group PLC
12.23. Reckitt Benckiser LLC.
12.24. ROHN HealthCar
12.25. Sanofi S.A.
12.26. Stanex Drugs & Chemicals Pvt. Ltd
12.27. Sterling Pharmaceutical Services LLC
12.28. Sun Pharmaceutical Industries Limited
12.29. Takeda Pharma
12.30. Teva Pharmaceutical Industries Ltd.
13. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/4npnpb
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/worldwide-consumer-healthcare-industry-to-2027—accelerated-use-of-online-sources-presents-opportunities-301464750.html
SOURCE Research and Markets
Santosh Rao, Head of Research at Manhattan Venture Partners, joins Yahoo Finance Live to discuss Netflix's fourth quarter earnings, the need to gain more subscribers, and competition in the streaming space.
The tech-heavy Nasdaq took off like a rocket this morning, and took semiconductor stock Nvidia (NASDAQ: NVDA) along for the ride. Just after noon ET, however, the rally started to sputter, and by the time trading for the day was done, not only had the Nasdaq given up all its gains, but Nvidia stock closed down 3.7% for the day. In the case of the Nasdaq as a whole, I fear that investors may have jumped the gun, presuming that after the Nasdaq met the definition for a stock market correction (down 10% from its high), the light would turn green for tech stocks to resume marching higher again.
The surface of the S&P 500 makes markets look calm. But look down just one layer, and you see some serious pain.
The yield-sensitive Nasdaq Composite Index on Wednesday logs its first close in correction territory since March. Here's what history says happens next.
CFA and owner of Portia Capital Management Michelle Connell joins Yahoo Finance Live to discuss Big Tech, energy and financial sector fund data, commodity futures, and Fed policy makers expecting three interest rate hikes in 2022.
(Bloomberg) — Most Read from BloombergEarly Omicron Breakthroughs Show mRNA Vaccines’ WeaknessLate Rout in Tech Sends Nasdaq 100 Into Correction: Markets WrapJeremy Grantham Doubles Down on Crash Call, Says Selloff Has StartedWhy Some Vaccinated People Resist Omicron and Others Don’tThailand to Resume Quarantine-Free Tourism as Covid EasesJeremy Grantham, the famed investor who for decades has been calling market bubbles, said the historic collapse in stocks he predicted a year ago is underway
Yahoo Finance's Brad Smith and Akiko Fujita discuss how the market is reacting to Peloton's production pause.
BioNTech (NASDAQ: BNTX) stock is taking the worst drubbing, down 19.7% as of the market close on Thursday. Moderna's (NASDAQ: MRNA) shares were sinking 17.2%. Novavax (NASDAQ: NVAX) and Ocugen (NASDAQ: OCGN) stocks were falling 18.5% and 16.2%, respectively.
Coronavirus stock Novavax (NASDAQ: NVAX) was a bit sickly on Thursday. The latest development comes from over the Pacific Ocean, specifically Australia. After market hours on Wednesday, Novavax announced that the nation's Therapeutic Goods Administration (TGA) has approved the provisional registration of NVX-CoV2373.
Market bulls should proceed with caution, warns a top strategist at Morgan Stanley.
For the fourth trading day in a row, Rivian (NASDAQ: RIVN) stock is falling. Down 3.5% as of 1:35 p.m. ET, Rivian stock actually costs less today than it did at its initial public offering (IPO) two months ago. First and foremost, Rivian is an unprofitable electric truck start-up.
Peloton shares get crushed on reports of a production halt.
Earlier, the Nasdaq dropped another more than 1%, adding to losses after sinking into a correction earlier this week.
Rallies are getting squashed and no lead appears to be safe for the stock market in recent trade. In fact, the Nasdaq Composite (COMP) intraday reversal on Thursday — when it was up 2.1% at its peak but ended down 1.3% — represented its largest reversal for a loss since April 7, 2020, according to Dow Jones Market Data. The disintegration of a big intraday uptrend comes after the Nasdaq Composite entered a correction — defined as a decline of at least 10% (but no more than 20%) from a recent peak — for the first time since March 8, 2021, and reflects the fragility of the market as it braces for a regime of higher interest rates and overall less-accommodative policy from the Federal Reserve.
Moderna has seen a meteoric rise in growth to become a household name as one of the leading COVID-19 vaccine manufacturers. However, the stock has slumped as of late — down around 60% from a September 2021 high of nearly $450.
Select analysts and investment banks see "high" return potential for these cannabis stocks.
(Bloomberg) — U.S. equity futures and Asian stocks fell Friday after a late-day reversal on Wall Street amid shaky company earnings, the prospect of tighter Federal Reserve monetary policy and U.S.-Russia tension.Most Read from BloombergEarly Omicron Breakthroughs Show mRNA Vaccines’ WeaknessJeremy Grantham Doubles Down on Crash Call, Says Selloff Has StartedLate Rout in Tech Sends Nasdaq 100 Into Correction: Markets WrapWhy Some Vaccinated People Resist Omicron and Others Don’tThailand to Resu
(Bloomberg) — When former President Donald Trump said in December that his nascent media company was raising $1 billion from a diverse group of institutional investors, the announcement was highly unusual in that it omitted the participants’ names.Most Read from BloombergEarly Omicron Breakthroughs Show mRNA Vaccines’ WeaknessWhy Some Vaccinated People Resist Omicron and Others Don’tLate Rout in Tech Sends Nasdaq 100 Into Correction: Markets WrapThailand to Resume Quarantine-Free Tourism as Cov
As earnings season ramps up, Netflix kicked the reporting period off for big tech when it unveiled its fourth quarter results after the bell on Thursday. Here were the main metrics from Netflix's report, compared to consensus estimates compiled by Bloomberg.
SoFi Technologies Inc. shares are soaring for the second-straight day on heavy volume as optimism continues to build for the company's banking ambitions.
